DCAT Names Officers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DCAT Names Officers


Lyra Myers, associate director and value creation agent at Roche, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: George Svokos, senior vice-president, product and portfolio management at Teva Pharmaceuticals U.S.A., as senior vice-president; Folker Ruchatz, senior vice-president, contract manufacturing business, biopharmaceuticals at Boehringer Ingelheim as finance officer; and Milton Boyer, president at OSO BioPharmaceuticals Manufacturing, LLC as vice-president. All will serve one-year terms.

DCAT is a nonprofit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, and related industries. The association provides services, programs and activities designed to support the business development objectives of its membership.

Source: DCAT

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here